MCID: MLT006
MIFTS: 47

Multidrug-Resistant Tuberculosis

Categories: Infectious diseases

Aliases & Classifications for Multidrug-Resistant Tuberculosis

MalaCards integrated aliases for Multidrug-Resistant Tuberculosis:

Name: Multidrug-Resistant Tuberculosis 12 15 17
Tuberculosis, Multidrug-Resistant 43 71
Tuberculosis Multidrug-Resistant 54

Classifications:



External Ids:

Disease Ontology 12 DOID:401
MeSH 43 D018088
NCIt 49 C128415
SNOMED-CT 67 423092005
UMLS 71 C0206526

Summaries for Multidrug-Resistant Tuberculosis

Disease Ontology : 12 A tuberculosis that is resistant to isoniazid and rifampicin, the two most powerful first-line anti-TB drugs.

MalaCards based summary : Multidrug-Resistant Tuberculosis, also known as tuberculosis, multidrug-resistant, is related to mycobacterium tuberculosis 1 and spondylitis. An important gene associated with Multidrug-Resistant Tuberculosis is INHA (Inhibin Subunit Alpha), and among its related pathways/superpathways are Allograft rejection and T cell receptor signaling pathway. The drugs Capreomycin and Clarithromycin have been mentioned in the context of this disorder. Affiliated tissues include testes, lung and t cells, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 74 Multi-drug-resistant tuberculosis (MDR-TB) is a form of tuberculosis (TB) infection caused by bacteria... more...

Related Diseases for Multidrug-Resistant Tuberculosis

Diseases related to Multidrug-Resistant Tuberculosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 500)
# Related Disease Score Top Affiliating Genes
1 mycobacterium tuberculosis 1 31.0 VDR TNF SLC11A1 INHA IL10 IFNG
2 spondylitis 30.9 TNF IL10 IFNG
3 acquired immunodeficiency syndrome 30.8 TNF IL10 IFNG CD4 ALB
4 immune deficiency disease 30.8 VDR TNF IL1A IL10 IFNG CD4
5 lung disease 30.7 TNF SLC11A1 IL1A IL10 IFNG ALB
6 pulmonary tuberculosis 30.6 VDR TNF SLC11A1 INHA IL10 IFNG
7 ocular tuberculosis 30.6 IFNG CD4
8 aspergillosis 30.6 TNF IL1A IL10 IFNG
9 exanthem 30.6 TNF IL10 IFNG CD4 ALB
10 central nervous system tuberculosis 30.6 TNF IFNG CD4
11 lymph node tuberculosis 30.6 TNF IFNG CD4
12 invasive aspergillosis 30.5 IL10 IFNG CD4
13 lymphadenitis 30.4 VDR TNF SLC11A1 IL10 IFNG CD4
14 chorioretinitis 30.4 TNF IL10 IFNG CD4
15 cytomegalovirus retinitis 30.4 TNF IL10 IFNG CD4
16 hashimoto thyroiditis 30.4 VDR TNF IL10 IFNG
17 bronchopneumonia 30.4 TNF IL10 CD4 ALB
18 plague 30.3 TNF IL10 CD4 ALB
19 paracoccidioidomycosis 30.3 TNF IL10 IFNG ALB
20 appendicitis 30.3 TNF IL10 IFNG ALB
21 pulmonary disease, chronic obstructive 30.3 TNF IL10 CD4 ALB
22 optic nerve disease 30.3 TNF EDNRB CD4 ALB
23 miliary tuberculosis 30.3 TNF IFNG CD4 ALB
24 intestinal obstruction 30.2 TNF EDNRB ALB
25 respiratory failure 30.2 TNF IL10 CD4 CAT ALB
26 meningitis 30.2 TNF IL1A IL10 IFNG CAT ALB
27 diarrhea 30.0 TNF IL10 IFNG ALB ABCB1
28 thrombocytopenia 30.0 TNF IL1A IL10 IFNG ALB ABCB1
29 peripheral nervous system disease 30.0 TNF SCN9A IL10 IFNG CD4 CAT
30 arthritis 29.9 TNF SLC11A1 IL1A IL10 IFNG ALB
31 extrapulmonary tuberculosis 29.9 VDR TNF SLC11A1 IL1A IL10 IFNG
32 psoriasis 29.8 VDR TNF IL1A IL10 IFNG CD4
33 leprosy 3 29.7 VDR TNF SLC11A1 IL10 IFNG HSPD1
34 crohn's disease 29.6 TNF SLC11A1 IL10 IFNG CD4 ALB
35 diabetes mellitus 29.1 VDR TNF IL1A IL10 IFNG HSPD1
36 punctate inner choroidopathy 10.6 TNF IL10
37 tropical endomyocardial fibrosis 10.6 TNF IL10
38 multifocal choroiditis 10.6 TNF IL10
39 hypothyroidism 10.6
40 palladium allergic contact dermatitis 10.6 TNF IL10
41 staphylococcal toxic shock syndrome 10.5 TNF IFNG
42 autoimmune myocarditis 10.5 TNF IFNG
43 type 1 diabetes mellitus 17 10.5 VDR SLC11A1
44 neuropathy 10.5
45 diabetes mellitus, insulin-dependent, 23 10.5 TNF CD4
46 polyarticular juvenile idiopathic arthritis 10.5 TNF IFNG
47 progressive myoclonus epilepsy 8 10.5 TNF IL1A IL10
48 idiopathic neutropenia 10.5 TNF IL1A IL10
49 conjunctivitis 10.5 TNF IL10 IFNG
50 rheumatoid arthritis interstitial lung disease 10.5 TNF CD4

Graphical network of the top 20 diseases related to Multidrug-Resistant Tuberculosis:



Diseases related to Multidrug-Resistant Tuberculosis

Symptoms & Phenotypes for Multidrug-Resistant Tuberculosis

MGI Mouse Phenotypes related to Multidrug-Resistant Tuberculosis:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.32 ABCB1 ALB EDNRA EDNRB HSPD1 IFNG
2 homeostasis/metabolism MP:0005376 10.28 ABCB1 ALB CAT CD4 CYP46A1 EDNRA
3 digestive/alimentary MP:0005381 10.24 ABCB1 ALB CD4 EDNRA EDNRB IFNG
4 growth/size/body region MP:0005378 10.23 ABCB1 CD4 EDNRA EDNRB HSPD1 IFNG
5 endocrine/exocrine gland MP:0005379 10.22 ABCB1 ALB CD4 EDNRA EDNRB IFNG
6 hematopoietic system MP:0005397 10.21 ABCB1 CD4 EDNRA EDNRB HSPD1 IFNG
7 immune system MP:0005387 10.21 ABCB1 ALB CD4 EDNRA EDNRB IFNG
8 mortality/aging MP:0010768 10.13 ABCB1 ALB CAT CD4 EDNRA EDNRB
9 integument MP:0010771 9.97 CD4 EDNRA EDNRB IFNG IL10 IL1A
10 muscle MP:0005369 9.76 ALB EDNRA EDNRB HSPD1 IFNG IL10
11 neoplasm MP:0002006 9.61 ALB CAT EDNRB IFNG IL10 IL1A
12 nervous system MP:0003631 9.4 ABCB1 CD4 EDNRA EDNRB HSPD1 IFNG

Drugs & Therapeutics for Multidrug-Resistant Tuberculosis

Drugs for Multidrug-Resistant Tuberculosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 60)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Capreomycin Approved Phase 4 11003-38-6 3000502
2
Clarithromycin Approved Phase 4 81103-11-9 84029
3
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
4
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
5
Streptomycin Approved, Vet_approved Phase 4 57-92-1 19649
6
Gatifloxacin Approved, Investigational Phase 4 112811-59-3 5379
7
Meropenem Approved, Investigational Phase 4 96036-03-2, 119478-56-7 441130 64778
8
Cilastatin Approved, Investigational Phase 4 82009-34-5 5280454 6435415
9
Rifabutin Approved, Investigational Phase 4 72559-06-9 6323490 46783538
10
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
11
Azithromycin Approved Phase 4 83905-01-5 447043 55185
12 Cytochrome P-450 CYP3A Inhibitors Phase 4
13 Thioacetazone Phase 4
14
Aldesleukin Approved Phase 2, Phase 3 85898-30-2, 110942-02-4
15
Ethambutol Approved Phase 3 74-55-5 3279 14052
16
Clofazimine Approved, Investigational Phase 2, Phase 3 2030-63-9 2794
17
Moxifloxacin Approved, Investigational Phase 2, Phase 3 354812-41-2, 151096-09-2 152946
18
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
19
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
20 Interleukin-2 Phase 2, Phase 3
21 Trace Elements Phase 3
22 Micronutrients Phase 3
23 Vitamins Phase 3
24 Vitamin B 6 Phase 3
25 Vitamin B Complex Phase 3
26 Nutrients Phase 3
27 Folate Phase 3
28 Vitamin B9 Phase 3
29 Norgestimate, ethinyl estradiol drug combination Phase 2, Phase 3
30 Lipid Regulating Agents Phase 3
31 Hypolipidemic Agents Phase 3
32 Antimetabolites Phase 3
33 Oxazolidinones Phase 2, Phase 3
34
Pyridoxal Experimental, Nutraceutical Phase 3 66-72-8 1050
35
Metronidazole Approved Phase 2 443-48-1 4173
36
Dolutegravir Approved Phase 2 1051375-16-6 54726191
37 Amoxicillin-Potassium Clavulanate Combination Phase 2
38 interferons Phase 2
39 Interferon-gamma Phase 2
40 Antiparasitic Agents Phase 2
41 Antiprotozoal Agents Phase 2
42 Antiviral Agents Phase 2
43 Integrase Inhibitors Phase 2
44 Anti-HIV Agents Phase 2
45 HIV Integrase Inhibitors Phase 2
46 Anti-Retroviral Agents Phase 2
47 Vaccines Phase 2
48 Immunologic Factors Phase 2
49
Minocycline Approved, Investigational Phase 1 10118-90-8 5281021
50
Etoricoxib Approved, Investigational Phase 1 202409-33-4 123619

Interventional clinical trials:

(show top 50) (show all 101)
# Name Status NCT ID Phase Drugs
1 The Pharmacokinetic Effect of Clarithromycin on the AUC0-12h of Linezolid in Multidrug-resistant and Extensively Drug-resistant Tuberculosis (MDR/XDR-TB) Patients Completed NCT01521364 Phase 4 Addition of different doses of clarithromycin.
2 The Individualized M(X) Drug-resistant TB Treatment Strategy Study A Strategy to Improve Treatment Outcomes in Patients With Drug-resistant TB Recruiting NCT03237182 Phase 4 Individualized TB treatment with multiple drugs;Standardized TB treatment with multiple drugs
3 Safety and Effectiveness of Delamanid-containing Regimen for Treatment of Patients With Multidrug-resistant Tuberculosis in China Not yet recruiting NCT04421495 Phase 4 Delamanid
4 Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide Unknown status NCT02120638 Phase 3 Pyrazinamide containing regimen;Regimen without Pyrazinamide
5 Study of Adjunctive rhIL-2 Therapy in Patients With MDR-TB That Improves Efficiency and Shortens Course Unknown status NCT03069534 Phase 2, Phase 3 RhIL-2
6 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of Delamanid (OPC-67683) Administered Orally as 200 mg Total Daily Dose for Six Months in Patients With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis Completed NCT01424670 Phase 3 Delamanid + OBR;Placebo + OBR
7 A Randomized Control Trial Of High-Dose Isoniazid Adjuvant Therapy For Multidrug Resistant Tuberculosis Completed NCT00513396 Phase 2, Phase 3 Isoniazid;Placebo
8 Evaluating Newly Approved Drugs for Multidrug-resistant TB (endTB): A Clinical Trial Recruiting NCT02754765 Phase 3 Bedaquiline;Delamanid;Clofazimine;Levofloxacin;Moxifloxacin;Linezolid;Pyrazinamide;Control arm MDR-TB regimen, consistent with WHO guidelines
9 A Randomised, Controlled, Open-Label, Phase II-III Trial to Evaluate the Safety and Efficacy of Regimens Containing Bedaquiline and Pretomanid for the Treatment of Adult Patients With Pulmonary Multidrug Resistant Tuberculosis Recruiting NCT02589782 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine;Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
10 Randomized, Placebo-controlled Study of Safety and Therapeutic Efficacy of the Drug FS-1 in the Oral Dosage Form in Drug-resistant Pulmonary Tuberculosis Active, not recruiting NCT02607449 Phase 3 FS-1;Placebo
11 Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB) Active, not recruiting NCT03568383 Phase 3 Delamanid (DLM);Isoniazid (INH)
12 A Phase 3 Partially-blinded, Randomized Trial Assessing the Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary Infection of Either Extensively Drug-resistant Tuberculosis (XDR-TB), Pre-XDR-TB or Treatment Intolerant or Non-responsive Multi-drug Resistant Tuberculosis (MDR-TB) Active, not recruiting NCT03086486 Phase 3 Pretomanid;Linezolid;Bedaquiline;Placebo Linezolid
13 An Open-Label, Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of a 4-month Treatment of Bedaquiline Plus Pretomanid Plus Moxifloxacin Plus Pyrazinamide (BPaMZ) Compared to a 6-month Treatment of HRZE/HR (Control) in Adult Participants With Drug-Sensitive Smear-Positive Pulmonary Tuberculosis (DS-TB) and a 6-month Treatment of BPaMZ in Adult Participants With Drug Resistant, Smear-Positive Pulmonary Tuberculosis (DR-TB) Active, not recruiting NCT03338621 Phase 2, Phase 3 Pretomanid;Bedaquiline;Moxifloxacin;Pyrazinamide;HRZE;HR
14 An Open Label, Randomized Controlled Trial to Establish the Efficacy and Safety of a Study Strategy Consisting of 6 Months of Bedaquiline (BDQ), Delamanid (DLM), and Linezolid (LNZ), With Levofloxacin (LVX) and Clofazimine (CFZ) Compared to the Current South African Standard of Care (Control Strategy) for 9 Months for the Treatment of Rifampicin Resistant Tuberculosis (RR-TB) Active, not recruiting NCT04062201 Phase 3 Bedaquiline Oral Tablet;Linezolid Oral Tablet;Delamanid in Oral Dosage Form;Clofazimine Oral Product;Levofloxacin Oral Tablet;Isoniazid Oral Product;Ethambutol Oral Product;Pyrazinamide Oral Product;Linezolid Oral Tablet;Clofazimine Oral Product;Levofloxacin Oral Tablet
15 Evaluating a New Treatment Regimen for Patients With Multidrug-resistant TB (MDR-TB) - a Prospective Open-label Randomised Controlled Trial Active, not recruiting NCT02454205 Phase 2, Phase 3 Linezolid;Bedaquiline;Levofloxacin;Pyrazinamide;Isoniazid;Ethionamide;Terizidone;Moxifloxacin;Kanamycin
16 STREAM: The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB Active, not recruiting NCT02409290 Phase 3 Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline);Moxifloxacin;Clofazimine;Ethambutol;Pyrazinamide;Isoniazid;Prothionamide;Kanamycin;Levofloxacin;Bedaquiline
17 Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q) Not yet recruiting NCT03896685 Phase 3 Bedaquiline 100 MG;Delamanid 50 MG Oral Tablet;Clofazimine Pill;Linezolid Pill;Control arm MDR-TB regimen, designed according to latest WHO guidelines
18 Novel Triple-dose Tuberculosis Retreatment Regimen: How to Overcome Resistance Without Creating More in Niger Not yet recruiting NCT04260477 Phase 3 6EH³R³Z;6EHRZ
19 Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial Not yet recruiting NCT03942354 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine;Directly observed therapy (DOT)
20 Economic Evaluation of New MDR TB Regimens (PRACTECAL EE) Not yet recruiting NCT04207112 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine;Standard Drugs
21 Pharmacokinetics and Pharmacodynamics Sub-study for TB-PRACTECAL Clinical Trial ( PRACTECAL-PKPD) Not yet recruiting NCT04081077 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine
22 Prospective, Randomized, Partially Blinded, Phase 3 Study of the Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB Withdrawn NCT03828201 Phase 3 Delamanid;Levofloxacin;Bedaquiline;Clofazimine;Linezolid
23 A Phase III Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Efficacy and Safety of TMC207 in Subjects With Sputum Smear-positive Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB) Withdrawn NCT01600963 Phase 3 Arm A Double-blind Phase: TMC207;Arm B Double-blind Phase: Placebo;Treatment Failure During Double-blind Phase: TMC207;Treatment Failure During Follow-up Phase: TMC207
24 Prospective, Randomized, Open Label Phase 3 Study of the Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin for Treatment of Patients With Fluoroquinolone-susceptible Multidrugresistant-‐Tuberculosis (MDR-TB) Withdrawn NCT02975570 Phase 3 Delamanid;Linezolid;Levofloxacin;Pyrazinamide;WHO MDR-TB regimen
25 A Phase 2, Multi-center, Non-controlled, Open-label Dose Escalation Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Orally Administered OPC-67683 Two Times Daily to Patients With Pulmonary Multidrug-Resistant Tuberculosis Refractory to Conventional Treatment Completed NCT01131351 Phase 2 OPC-67683
26 Phase 2, Open-label, Multiple-dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Delamanid (OPC-67683) in Pediatric Multidrug-resistant Tuberculosis Patients on Therapy With an Optimized Background Regimen of Anti-tuberculosis Drugs Over a 6-Month Treatment Period Completed NCT01859923 Phase 2 100 mg Delamanid;50 mg Delamanid;25 mg Pediatric Formulation Delamanid;10 mg Delamanid Pediatric Formulation;5 mg Delamanid Pediatric Formulation;Optimized Background Regimen
27 A Phase 2, Multi-center, Uncontrolled, Open-label Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683 as 100 mg BID With Optional Titration to 200 mg BID for up to Six Months Exposure in Patients With Pulmonary Multi-drug Resistant Tuberculosis Completed NCT02573350 Phase 2 Delamanid
28 A Multi Center, Randomized, Double-blind, Placebo-controlled Phase 2 Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Multiple Doses of OPC 67683 in Patients With Pulmonary Sputum Culture-Positive, Multidrug-resistant Tuberculosis Completed NCT00685360 Phase 2 OPC-67683;OPC-67683;Placebo
29 TBTC Study 30: A Phase I/II Pilot Study for Evaluation of Low Dose, Once Daily, Linezolid Plus Optimized Background Therapy (OBT) Versus Placebo Plus OBT for the Treatment of Multi-drug Resistant Tuberculosis Completed NCT00664313 Phase 1, Phase 2 Linezolid;Placebo
30 A Phase II, Open-label Trial With TMC207 as Part of a Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Subjects With Sputum Smear-positive Pulmonary Infection With MDR-TB. Completed NCT00910871 Phase 2 TMC207;Background Regimen (BR) for MDR-TB
31 An Open-Label Study to Explore the Safety, Efficacy and Pharmacokinetics of TMC207 in Japanese Patients With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB) Completed NCT02365623 Phase 2 TMC207 (bedaquiline);Background Regimen (BR)
32 Linezolid Pharmacokinetics and Pharmacodynamics in the Treatment of Multi-Drug Resistant and Extensively-Drug Resistant Tuberculosis Completed NCT00691392 Phase 1, Phase 2 Linezolid;Microcrystalline Methylcellulose - Placebo
33 Treatment of Multiply Drug Resistant Tuberculosis With Interferon Gamma: A Phase I/II Dose Escalation Trial Completed NCT00001407 Phase 2 Interferon Gamma
34 A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Metronidazole Combined With Antituberculous Chemotherapy vs. Antituberculous Chemotherapy With Placebo in Subjects With Multi-Drug Resistant Pulmonary Tuberculosis Completed NCT00425113 Phase 2 Metronidazole
35 A Phase 2a, Randomized, 2-Arm, Open-Label, Clinical Trial of the Efficacy of Linezolid Combined With Antituberculous Therapy in Subjects With Extensively Drug-Resistant (XDR) Pulmonary Tuberculosis Completed NCT00727844 Phase 2 Immediate Start Linezolid;Delayed Start Linezolid
36 A Randomized, Double-Blinded, Placebo-Controlled, Phase II Study of the Safety and Efficacy of Inhaled Interferon Gamma-1b With Antimycobacterial in Previously Treated or Moderate to Severe Pulmonary Mycobacterium Avium Complex (MAC) Infection Completed NCT00021567 Phase 2 Interferon Gamma for Aerosol
37 Delamanid, Linezolid, Levofloxacin, and Pyrazinamide for the Treatment of Patients With Fluoroquinolone-sensitive MDR-TB: A Phase 2/3, Multicenter, Randomized, Open-label, Clinical Trial Recruiting NCT02619994 Phase 2 Linezolid;Delamanid;Levofloxacin;Pyrazinamide;Locally-used WHO-approved MDR-TB regimen in Korea
38 A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB Recruiting NCT03141060 Phase 1, Phase 2 Delamanid;Optimized multidrug background regimen (OBR) for children with MDR-TB
39 A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) in Combination With Optimized Individualized Multidrug-Resistant Tuberculosis (MDR-TB) Therapy in HIV-Infected and HIV-Uninfected Infants, Children and Adolescents With MDR-TB Disease Recruiting NCT02906007 Phase 1, Phase 2 Bedaquiline
40 A Phase 2, Open-label, Multicenter, Single-arm Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Anti-mycobacterial Activity of TMC207 in Combination With a Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for the Treatment of Children and Adolescents 0 Months to <18 Years of Age Who Have Confirmed or Probable Pulmonary MDR-TB Recruiting NCT02354014 Phase 2 Bedaquiline (TMC207);Background Regimen (BR)
41 Prospective, Randomized, Blinded Phase II Pharmacokinetic/Pharmacodynamic Study of the Efficacy and Tolerability of Levofloxacin in Combination With Optimized Background Regimen for the Treatment of MDR-TB Active, not recruiting NCT01918397 Phase 2 Levofloxacin;Optimized background regimen (OBR)
42 A Trial of the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, Among Participants Taking Multidrug Treatment for Drug-Resistant Pulmonary Tuberculosis Active, not recruiting NCT02583048 Phase 2 Bedaquiline;Delamanid;Dolutegravir;Multidrug Background Treatment (MBT) for TB
43 Double-Blind, Randomized, Placebo-Controlled Phase IIa Clinical Trial to Investigate the Safety and Immunogenicity of RUTI® Therapeutic Vaccination in Patients With Multi-Drug Resistant Tuberculosis After Successful Intensive-phase Treatment. Not yet recruiting NCT02711735 Phase 2
44 Phase 1, Open-label, Multiple-dose, and Age De-escalation Trial to Assess the Pharmacokinetics, Safety and Tolerability of Delamanid (OPC 67683) in Pediatric Multidrug-resistant Tuberculosis Patients on Therapy With an Optimized Background Regimen of Anti-tuberculosis Drugs Completed NCT01856634 Phase 1 100 mg Delamanid;50 mg Delamanid;25 mg Pediatric Formulation Delamanid;10 mg Delamanid Pediatric Formulation;5 mg Delamanid Pediatric Formulation;Optimized Background Regimen
45 An Open-label, Randomized, Four-period, Crossover Study in Two Panels of Healthy Adult Subjects to Assess the Relative Bioavailability, Food Effect, and Dose-dependence of Single-dose Immediate-release and Single-dose Dispersible Formulations of Pretomanid Completed NCT04309656 Phase 1 Pretomanid
46 Clinical Study on Adoptive Treatment of Multidrug Resistant Pulmonary Tuberculosis With Allogeneic γδT Cells Recruiting NCT03575299 Phase 1 Conventional treatment
47 Pharmacokinetic Evaluation and Local Tolerability of Dry Powder Amikacin Via the Cyclops™ in Patients With Drug Susceptible Tuberculosis Recruiting NCT04249531 Phase 1 Amikacin Inhalation Dry Powder;Amikacin Injectable Product
48 Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the Multidrug-resistant Tuberculosis Pandemic; an Open Label Phase I Clinical Trial of the Therapeutic TB H56:IC31 Vaccine and Cyclooxygenase-inhibitors Active, not recruiting NCT02503839 Phase 1 etoricoxib
49 A Phase 1 Trial to Evaluate the Male Reproductive Safety of 26-weeks Dosing of Once Daily 200mg Pretomanid in Healthy Volunteers Not yet recruiting NCT04179500 Phase 1 Pretomanid
50 Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis Treatment in Karakalpakstan, Uzbekistan Unknown status NCT02496572 Short course MDR-TB treatment regimen

Search NIH Clinical Center for Multidrug-Resistant Tuberculosis

Cochrane evidence based reviews: tuberculosis, multidrug-resistant

Genetic Tests for Multidrug-Resistant Tuberculosis

Anatomical Context for Multidrug-Resistant Tuberculosis

MalaCards organs/tissues related to Multidrug-Resistant Tuberculosis:

40
Testes, Lung, T Cells, Skin, Liver, Whole Blood, Thyroid

Publications for Multidrug-Resistant Tuberculosis

Articles related to Multidrug-Resistant Tuberculosis:

(show top 50) (show all 3337)
# Title Authors PMID Year
1
Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. 54 61
9041419 1997
2
What steps can researchers take to increase research uptake by policymakers? A case study in China. 61
32386212 2020
3
A sister lineage of the Mycobacterium tuberculosis complex discovered in the African Great Lakes region. 61
32518235 2020
4
Delamanid resistance: update and clinical management. 61
32521000 2020
5
Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. 61
32553880 2020
6
Whole-genome sequencing analysis of multidrug-resistant Mycobacterium tuberculosis from Java, Indonesia. 61
32579102 2020
7
Combination of Xpert MTB/RIF and MTBDRplus for Diagnosing Tuberculosis in a Chinese District. 61
32504464 2020
8
A Review of Clinical Pharmacokinetic and Pharmacodynamic Relationships and Clinical Implications for Drugs Used to Treat Multi-drug Resistant Tuberculosis. 61
31925745 2020
9
Opportunities and challenges of using five-membered ring compounds as promising antitubercular agents. 61
31904877 2020
10
Is effective patient support missing in the global response to multidrug-resistant tuberculosis? 61
32553006 2020
11
Distribution of Linezolid in Tuberculosis Lesions in Patients with Spinal Multidrug-Resistant Tuberculosis. 61
32366717 2020
12
Meta-analysis on Effectiveness and Safety of Moxifloxacin in Treatment of Multidrug Resistant Tuberculosis in Adults. 61
32569195 2020
13
Rising challenge of multidrug-resistant tuberculosis in China: a predictive study using Markov modeling. 61
32513262 2020
14
Interim treatment outcomes in multidrug-resistant tuberculosis using bedaquiline and/or delamanid in South Korea. 61
32421540 2020
15
Molecular epidemiological study of multidrug-resistant tuberculosis isolated from sputum samples in Eastern Cape, South Africa. 61
31923728 2020
16
Citywide Transmission of Multidrug-resistant Tuberculosis Under China's Rapid Urbanization: A Retrospective Population-based Genomic Spatial Epidemiological Study. 61
31504306 2020
17
Prevalence of multidrug-resistant tuberculosis in Latin America and the Caribbean: a systematic review and meta-analysis. 61
32506718 2020
18
Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study. 61
32554740 2020
19
Genotypic and phenotypic characterization of Mycobacterium tuberculosis resistance against fluoroquinolones in the northeast of Iran. 61
32487030 2020
20
Time to sputum culture conversion and its associated factors among multidrug-resistant tuberculosis patients in Eastern Africa: A systematic review and meta-analysis. 61
32535296 2020
21
Nomogram to predict multidrug-resistant tuberculosis. 61
32505203 2020
22
Isoniazid Preventive Therapy in Contacts of Multidrug-resistant Tuberculosis. 61
32551948 2020
23
Mycobacterium tuberculosis ribosomal protein S1 (RpsA) and variants with truncated C-terminal end show absence of interaction with pyrazinoic acid. 61
32433489 2020
24
Fluoroquinolone resistance and mutational profile of gyrA in pulmonary MDR tuberculosis patients. 61
32393213 2020
25
The ethical imperative to relieve suffering for people with tuberculosis by ensuring access to palliative care. 61
32553036 2020
26
Intraocular deposits and cataracts after long-term rifabutin intake: A case report. 61
32481272 2020
27
Efflux pump inhibitors as a promising adjunct therapy against drug resistant tuberculosis: a new strategy to revisit mycobacterial targets and repurpose old drugs. 61
32434397 2020
28
Radiosynthesis and Biodistribution of 18F-Linezolid in Mycobacterium tuberculosis-Infected Mice Using Positron Emission Tomography. 61
32243132 2020
29
Highly Enantioselective, Hydrogen-Bond-Donor Catalyzed Additions to Oxetanes. 61
32364378 2020
30
Understanding the drug exposure-response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug-resistant tuberculosis. 61
31840278 2020
31
Determinants of multidrug-resistant tuberculosis in São Paulo-Brazil: a multilevel Bayesian analysis of factors associated with individual, community and access to health services. 61
32358845 2020
32
First case report in Latin America: Oral treatment of multidrug-resistant tuberculosis with delamanid and bedaquiline in combination with linezolid, moxifloxacin and clofazimine following a DRESS syndrome in a peruvian patient. 61
32444311 2020
33
A Rapid and Accurate Detection Approach for Multidrug-Resistant Tuberculosis Based on PCR-ELISA Microplate Hybridization Assay. 61
32447387 2020
34
The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa. 61
32186925 2020
35
Patient satisfaction with directly observed treatment and multidrug-resistant tuberculosis injection administration by lay health workers in rural Eswatini. 61
32501027 2020
36
Economic evaluation of short treatment for multidrug-resistant tuberculosis, Ethiopia and South Africa: the STREAM trial. 61
32514196 2020
37
Multidrug-resistant tuberculosis of lumbosacral spine producing extensive destruction with lumbosacral kyphosis. 61
32414775 2020
38
Progress in the roll-out of multidrug-resistant tuberculosis (MDR-TB) treatments. 61
32398206 2020
39
Multidrug-resistant tuberculosis transmission among middle school students in Zhejiang Province, China. 61
32460836 2020
40
Contributing risk factors towards the prevalence of multidrug-resistant tuberculosis in Malaysia: A systematic review. 61
32275233 2020
41
Pretreatment Out-of-Pocket Expenses for Presumptive Multidrug-Resistant Tuberculosis Patients, India, 2016-2017. 61
32310069 2020
42
Quality of life, tuberculosis and treatment outcome; a case-control and nested cohort study. 61
32366485 2020
43
Successful bedaquiline-containing antimycobacterial treatment in post-traumatic skin and soft-tissue infection by Mycobacterium fortuitum complex: a case report. 61
32448204 2020
44
Neurocognitive functioning in MDR-TB patients with and without HIV in KwaZulu-Natal, South Africa. 61
32428324 2020
45
International epidemiology databases to evaluate AIDS (IeDEA) in sub-Saharan Africa, 2012-2019. 61
32414825 2020
46
[Analysis on drug sensitivity spectrum of 167 multidrug-resistant Mycobacterium tuberculosis in China]. 61
32447922 2020
47
Closure of pulmonary cavity of a multidrug-resistant tuberculosis patient with catheter insertion - A case report. 61
32042929 2020
48
Multidrug-resistant tuberculosis in the Kharkiv Region, Ukraine. 61
32398197 2020
49
[Kanamycin-induced ototoxicity during treatment of multidrug-resistant tuberculosis]. 61
32278508 2020
50
Reply to: 'High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients'. 61
32057917 2020

Variations for Multidrug-Resistant Tuberculosis

Expression for Multidrug-Resistant Tuberculosis

Search GEO for disease gene expression data for Multidrug-Resistant Tuberculosis.

Pathways for Multidrug-Resistant Tuberculosis

Pathways related to Multidrug-Resistant Tuberculosis according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.54 TNF IL1A IL10 IFNG HSPD1 CD4
2
Show member pathways
12.46 TNF IL1A IL10 IFNG CD4
3
Show member pathways
12.45 TNF IL1A IL10 IFNG CD4
4
Show member pathways
12.23 TNF IFNG CAT ALB
5
Show member pathways
12.22 SLC11A1 DEFA3 DEFA1 CD4
6
Show member pathways
12.15 TNF IL1A IL10 IFNG
7 12.06 TNF IL1A IL10 HSPD1
8 11.8 TNF IL10 IFNG CD4
9
Show member pathways
11.73 TNF IL10 IFNG CD4
10 11.69 VDR TNF IL1A IL10 IFNG HSPD1
11 11.66 TNF IL1A IL10
12 11.57 TNF IL10 IFNG CD4
13
Show member pathways
11.56 TNF IL1A IFNG
14 11.49 TNF IL10 IFNG CD4
15 11.44 TNF IL10 IFNG
16 11.42 TNF IL1A IL10
17 11.38 IL10 IFNG CD4
18 11.24 TNF IL10 IFNG
19
Show member pathways
11.21 TNF IL10 IFNG
20 11.18 TNF IL1A IL10
21 11.11 VDR TNF IL1A IFNG
22 10.48 TNF IL1A IL10 IFNG CD4

GO Terms for Multidrug-Resistant Tuberculosis

Cellular components related to Multidrug-Resistant Tuberculosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 TUB TNF INHA IL1A IL10 IFNG
2 membrane raft GO:0045121 9.46 TNF HSPD1 EDNRB CD4
3 extracellular space GO:0005615 9.32 TNF INHA IL1A IL10 IFNG HSPD1

Biological processes related to Multidrug-Resistant Tuberculosis according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.04 VDR TNF SLC11A1 IL1A IFNG
2 positive regulation of protein phosphorylation GO:0001934 9.9 TNF IFNG EDNRB CD4
3 defense response to bacterium GO:0042742 9.89 TNF SLC11A1 IL10 DEFA3 DEFA1
4 response to lipopolysaccharide GO:0032496 9.88 SLC11A1 IL10 HSPD1 EDNRB
5 immune response GO:0006955 9.87 TNF SLC11A1 IL1A IL10 IFNG DEFA1
6 response to glucocorticoid GO:0051384 9.79 TNF IL10 HSPD1
7 antimicrobial humoral response GO:0019730 9.77 SLC11A1 DEFA3 DEFA1
8 positive regulation of interferon-gamma production GO:0032729 9.73 TNF SLC11A1 HSPD1
9 response to activity GO:0014823 9.72 IL10 HSPD1 CAT
10 defense response to Gram-negative bacterium GO:0050829 9.67 SLC11A1 DEFA3 DEFA1 CD4
11 negative regulation of amyloid-beta clearance GO:1900222 9.64 TNF IFNG
12 positive regulation of MHC class II biosynthetic process GO:0045348 9.63 IL10 IFNG
13 membrane disruption in other organism GO:0051673 9.63 DEFA3 DEFA1
14 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.62 TNF IFNG
15 endothelial cell apoptotic process GO:0072577 9.61 TNF IL10
16 endothelin receptor signaling pathway GO:0086100 9.61 EDNRB EDNRA
17 defense response to protozoan GO:0042832 9.61 SLC11A1 IL10 DEFA1
18 negative regulation of cytokine production involved in immune response GO:0002719 9.58 TNF IL10
19 positive regulation of tumor necrosis factor secretion GO:1904469 9.58 IL1A IFNG HSPD1
20 negative regulation of cytokine secretion involved in immune response GO:0002740 9.57 TNF IL10
21 positive regulation of phagocytosis GO:0050766 9.56 TUB TNF SLC11A1 IFNG
22 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.54 TNF IFNG
23 receptor biosynthetic process GO:0032800 9.52 TNF IL10
24 response to inactivity GO:0014854 9.51 IL10 CAT
25 positive regulation of vitamin D biosynthetic process GO:0060557 9.48 TNF IFNG
26 positive regulation of nitrogen compound metabolic process GO:0051173 9.46 TNF IFNG
27 positive regulation of interleukin-6 secretion GO:2000778 9.46 TNF IL1A IFNG HSPD1
28 positive regulation of cytokine secretion GO:0050715 9.26 TNF IL1A IL10 IFNG
29 cellular response to lipopolysaccharide GO:0071222 9.17 VDR TNF IL1A IL10 EDNRB DEFA3

Molecular functions related to Multidrug-Resistant Tuberculosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.02 TNF INHA IL1A IL10 IFNG
2 endothelin receptor activity GO:0004962 8.96 EDNRB EDNRA

Sources for Multidrug-Resistant Tuberculosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....